Celltrion submits European Phase 3 clinical trial application for CT-P13 SC in rheumatoid arthritis, seeking label expansion
Celltrion has submitted a global Phase 3 clinical trial application for CT-P13 SC in rheumatoid arthritis to the European Medicines Agency EMA under both Part 1 and Part 2 simultaneously.
This trial is a randomized placebo-controlled double-blind parallel-group study involving 296 patients with moderate to severe active rheumatoid arthritis over a 52-week treatment period to evaluate efficacy and safety.
CT-P13 SC is a subcutaneous formulation of the infliximab biosimilar Remsima IV, aiming to expand its indications beyond ulcerative colitis and Crohn's disease to include rheumatoid arthritis.
Investors should note that the probability of final regulatory approval for a clinical-stage drug is statistically around 10%, and unfavorable results could alter or abandon commercialization plans.
[AI Summary]This disclosure marks a clinical milestone for Celltrion to expand the label of an existing product. While it carries high uncertainty given the early stage and low success probability, successful development could open a significant new revenue stream with enhanced patient convenience.
KOSPI Filing Information
Major Management Matters Related To Investment Decision (CTP13 SC (Zymfentra) European Phase 3 Clinical Trial Plan Application (Part1&2) (Rheumatoid Arthritis Patients))